drugset / Trial / NCT01165359
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults
RandomizedParallel-groupDouble-blindTreatment
Summary
Hepatitis C (HCV) is a disease that affects the liver. ITX 5061 is a new medication that is being tested to treat HCV. This study will evaluate the safety of ITX 5061 and examine different doses of the medication to evaluate which dose is the most effective at lowering the amount of HCV in the blood.
Timeline
- Start
- 2010-09
- Primary completion
- 2012-02
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ITX 5061 | Small molecule | 25 mg | — |
| Subject | ITX 5061 | Small molecule | 75 mg | — |
| Subject | ITX 5061 | Small molecule | 150 mg | — |